Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Transl Res. 2018 Dec 25;207:19–29. doi: 10.1016/j.trsl.2018.12.004

Fig 2.

Fig 2.

sFLT-1, sENDOGLIN, and PlGF in preeclampsia-affected pregnancies. Mean (±SE) levels of soluble fms-like tyrosine kinase 1 (sFLT-1) A, soluble endoglin (sENDOGLIN) B, and placental growth factor (PlGF) C, in plasma and serum of healthy pregnant women and pregnant women affected by preeclampsia (PE) between 35 and 40 weeks of pregnancy as measured by ELISA. sFLT-1 (A) and sENDOGLIN (B) concentrations are significantly increased in women affected by PE, compared to age-matched controls (t test, ****P < 0.0001). Levels of PlGF (C) are significantly decreased in PE samples as compared to controls (t test, ***P < 0.001). Gray dots and squares represent plasma samples from control and PE-affected pregnant women, respectively. Black dots and squares represent serum samples from control and PE-affected women, respectively. ELISAs, enzyme-linked immunosorbent assays.